Ewolf and Peter, excellent questions and discussion. Under point 3, Peter, I would expand that to scientific and medical critical analysis, and experience base to not make the same mistakes over again, as well as to capitalize on previous successes that have occurred both within a company and in this sector in a more general sense. I suspect that you factor those issues into your overall judgement category. The one point that you strongly make, Peter, and that I strongly concur is that drug development is risky, and of course that is where a depth and breadth of pipeline comes into play as well as savvy financing.
On a somewhat related note, I have my views on near term investing in the healthcare sector, and we are at a 5 year high on several general market indices. Due to the high correlation of individual stocks to the indices, we need to keep in mind the market tone for either holding or buying into stocks, especially the biotechs. Though there is a disdain for the charts on this thread, I have asked on another thread for people to provide their views on the macro picture and on sector outlooks. If any are interested, please see:
Message 22340997
BJ |
